| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Molecular Medicine (T.J.S.), Department of Medicine, Harbor-University of California Los Angeles Medical Center, Torrance, California 90502; The Jules Stein Eye Institute (T.J.S.), David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 (T.J.S.); and Long Beach Veterans Administration Healthcare System (T.J.S., N.H.), Long Beach, California 90822
Address all correspondence and requests for reprints to: Terry J. Smith, M.D., Division of Molecular Medicine, Building C-2, Harbor-University of California Los Angeles Medical Center, 1124 West Carson Street, Torrance, California 90502. E-mail: tjsmith{at}ucla.edu.
A distinctive histopathological feature associated with thyroid-associated ophthalmopathy is the disordered accumulation of the glycosaminoglycan, hyaluronan, in orbital connective tissues. This often occurs in the context of dramatic inflammation and tissue remodeling. Orbital fibroblasts exhibit a novel phenotype including exaggerated responses to cytokines. Here, we report for the first time the ability of IgG isolated from the sera of patients with Graves disease (GD-IgG) to provoke in orbital fibroblasts the synthesis of hyaluronan. The effect of GD-IgG can be reproduced by IGF-I, appears to be mediated through the IGF-I receptor, and is abolished with glucocorticoid treatment. TSH failed to influence the synthesis of hyaluronan. In contrast to the effects in GD fibroblasts, cultures derived from donors without known thyroid disease fail to respond to GD-IgG or IGF-I. The observation that hyaluronan production is induced by GD-IgG in fibroblasts suggests that the IGF-I receptor and its activating antibodies may represent a key pathway through which important pathogenic events in thyroid-associated ophthalmopathy are mediated.
This article has been cited by other articles:
![]() |
R. S. Douglas, V. Naik, C. J. Hwang, N. F. Afifiyan, A. G. Gianoukakis, D. Sand, S. Kamat, and T. J. Smith B Cells from Patients with Graves' Disease Aberrantly Express the IGF-1 Receptor: Implications for Disease Pathogenesis J. Immunol., October 15, 2008; 181(8): 5768 - 5774. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tsui, V. Naik, N. Hoa, C. J. Hwang, N. F. Afifiyan, A. Sinha Hikim, A. G. Gianoukakis, R. S. Douglas, and T. J. Smith Evidence for an Association between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors: A Tale of Two Antigens Implicated in Graves' Disease J. Immunol., September 15, 2008; 181(6): 4397 - 4405. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Douglas, A. G. Gianoukakis, S. Kamat, and T. J. Smith Aberrant Expression of the Insulin-Like Growth Factor-1 Receptor by T Cells from Patients with Graves' Disease May Carry Functional Consequences for Disease Pathogenesis J. Immunol., March 1, 2007; 178(5): 3281 - 3287. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. El Fassi, C. H Nielsen, H. C Hasselbalch, and L. Hegedus The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur. J. Endocrinol., May 1, 2006; 154(5): 623 - 632. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Gilbert, A. G. Gianoukakis, S. Salehi, J. Moorhead, P. V. Rao, M. Z. Khan, A. M. McGregor, T. J. Smith, and J. P. Banga Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves' disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways. J. Immunol., April 15, 2006; 176(8): 5084 - 5092. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Drexhage Are There More than Antibodies to the Thyroid-Stimulating Hormone Receptor that Meet the Eye in Graves' Disease? Endocrinology, January 1, 2006; 147(1): 9 - 12. [Full Text] [PDF] |
||||
![]() |
R. Han and T. J. Smith T Helper Type 1 and Type 2 Cytokines Exert Divergent Influence on the Induction of Prostaglandin E2 and Hyaluronan Synthesis by Interleukin-1{beta} in Orbital Fibroblasts: Implications for the Pathogenesis of Thyroid-Associated Ophthalmopathy Endocrinology, January 1, 2006; 147(1): 13 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Feldon, D. J. J. Park, C. W. O'Loughlin, V. T. Nguyen, S. Landskroner-Eiger, D. Chang, T. H. Thatcher, and R. P. Phipps Autologous T-Lymphocytes Stimulate Proliferation of Orbital Fibroblasts Derived from Patients with Graves' Ophthalmopathy Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 3913 - 3921. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. J. Park, T. Y. Kim, S. H. Lee, H. Kim, S. W. Kim, M. Shong, Y. K. Yoon, B. Y. Cho, and D. J. Park p66Shc Expression in Proliferating Thyroid Cells Is Regulated by Thyrotropin Receptor Signaling Endocrinology, May 1, 2005; 146(5): 2473 - 2480. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Han and T. J. Smith Induction by IL-1{beta} of Tissue Inhibitor of Metalloproteinase-1 in Human Orbital Fibroblasts: Modulation of Gene Promoter Activity by IL-4 and IFN-{gamma} J. Immunol., March 1, 2005; 174(5): 3072 - 3079. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |